Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

KSQ Therapeutics

Request full access

The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates

Cambridge, United StatesFounded 2015Biotech & Life Sciences

About KSQ Therapeutics

KSQ Therapeutics is a biotechnology startup operating in the healthcare sector, specifically in the development of innovative cancer treatments. The company's primary focus is on the discovery and development of the best therapeutic targets for disease intervention, with a particular emphasis on solid tumors. KSQ Therapeutics serves a broad range of clients, including patients suffering from various forms of cancer and healthcare providers seeking effective treatment options.

The company's business model revolves around the development and commercialization of its proprietary eTIL (gene-edited Tumor Infiltrating Lymphocyte) cell therapy products. These products, developed using KSQ's CRISPRomics platform and CRISPR2 technology, have shown promising results in preclinical tumor models. The company's lead programs, KSQ-001 and KSQ-004, aim to maximize the ability of tumor-targeting T cells to destroy solid tumors.

KSQ Therapeutics generates revenue through the development, clinical testing, and eventual commercialization of its eTIL products. The company's simplified ExPRESS™ eTIL manufacturing process promises quicker turnaround times from tumor to vein, potentially improving the patient experience and reducing costs.

The company operates in a highly competitive market, with many other biotech companies also working on innovative cancer treatments. However, KSQ's unique approach and promising early results set it apart in this field.

Source: Dealroom company data

At a glance

Status
Operational
Employees
60
Open positions
None listed
Dealroom signal
63.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Genetics and genomics, Crispr, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Sep 2018 $80M $320M Polaris Partners · Baillie Gifford · Invus · ARCH Venture Partners —
LATE VCOther financing Oct 2017 $76M $304M Alexandria Equities · Polaris Partners · ARCH Venture Partners · Flagship Pioneering ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

KSQ Therapeutics website traffic

Latest recorded traffic for KSQ Therapeutics is 4.3K monthly website visits, up 38.7% over the last three months. KSQ Therapeutics's team declined 16.7% over the past year.

Latest monthly visits4.3K 3-month web change+38.7% 1-year team growth-16.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

KSQ Therapeutics in the Cambridge ecosystem

Live from Dealroom

The KSQ Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later7 investors entered at this stage

Other known investors1 additional known investor

  • Massachusetts Institute of Technology
Team profiled 17 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States98.5%
🇮🇱 Israel1.5%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about KSQ Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See KSQ Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.